In 1971, the founders of the International Fertility Research Program — now FHI 360 — committed to developing and evaluating contraceptive technologies to meet the needs and desires of people in low-income countries. Since then, FHI 360 researchers have conducted hundreds of clinical trials and research studies to assess the safety, efficacy, acceptability and potential non-contraceptive benefits of many of the contraceptives available today around the globe.
Our current portfolio — anchored by two major research awards, the Contraceptive Technology Innovation Initiative and Innovate FP (which builds on the previous Envision FP award) — spans research across multiple stages of contraceptive product development. We are developing and evaluating technologies including implants, injectables, microneedle patches and intrauterine devices.
Contraceptive product research, development and introduction projects
Our innovative portfolio of contraceptive research and development and introduction activities are responding to user preferences and filling gaps in the method mix.
